Diagnostic Center | June 02, 2023
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
_256_275.jpg)